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Many neurodegenerative diseases, such as Alzheimer’s disease, Parkinson disease,
vascular and frontotemporal dementias, as well as other chronic neurological pathologies,
are characterized by slowdevelopmentwith a long asymptomatic period followed by a stage
with mild clinical symptoms. As a consequence, these serious pathologies are diagnosed
late in the course of a disease, when massive death of neurons has already occurred and
effective therapeutic intervention is problematic.Thus, the development of screening tests
capable of detecting neurodegenerative diseases during early, preferably asymptomatic,
stages is a high unmet need. Since such tests are to be used for screening of large
populations, they should be non-invasive and relatively inexpensive. Further, while subjects
identiﬁed by screening tests can be further tested with more invasive and expensive
methods, e.g., analysis of cerebrospinal ﬂuid or imaging techniques, to be of practical
utility screening tests should have high sensitivity and speciﬁcity. In this review, we discuss
advantages and disadvantages of various approaches to developing screening tests based
on analysis of circulating cell-free microRNA (miRNA). Applications of circulating miRNA-
based tests for diagnosis of acute and chronic brain pathologies, for research of normal
brain aging, and for disease and treatment monitoring are also discussed.
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INTRODUCTION
There are several basic types of clinical tests: (i) genetic tests that
help predict predisposition to a particular disease; (ii) screening
tests,which are applied to a large population for early detectionof a
disease, preferably prior to its clinical manifestation; (iii) diagnos-
tic tests, which are applied when a person has clinical symptoms
of a disease or when the pathology has been detected by a screen-
ing test; (iv) predictive tests aimed to predict the disease outcome
and drug sensitivity; and (v) disease and treatment monitoring
tests. Screening tests are most important for the early detection
and successful treatment of a disease, especially if its progression
leads to signiﬁcant changes in the nature of underlying patholog-
ical processes. Cancers and neurodegenerative diseases are most
common examples of such diseases. Cancer progression leads to
tumor invasion into surrounding tissues, metastasis and clonal
evolution, which dramatically complicates treatment (Richards,
2009; Caldas, 2012). Similarly, progression of neurodegenerative
diseases, leads to a switch from metabolic abnormalities to neu-
rite and synapse destruction and ﬁnally to irreversible neuronal
death (Bredesen, 2009; Snyder et al., 2012). Further, disease pro-
gression leads to involvement of new brain areas and cell types
in the pathology (von Bernhardi and Inestrosa, 2008). The new
diagnostic methods based on imaging techniques and analysis of
proteins and other components in the cerebrospinal ﬂuid (CSF)
have been developed recently (Apostolova et al., 2010; Fagan et al.,
2011; Mori et al., 2012); these methods, however, are not suitable
for the ﬁrst line screening due to their invasiveness and relatively
high cost.
EARLY DIAGNOSIS OF NEUROLOGIC DISEASES
There are hundreds of brain disorders and many ways to classify
them; however, from the viewpoint of diagnostics it is helpful
to consider the diseases based on the need for different types of
diagnostics, and on the underlying pathologic processes that need
to be accurately and speciﬁcally detected by successful diagnostic
tests.
First of all, all neurologic diseases fall into two large groups:
acute and chronic pathologies. Obviously, there is a need in
diagnostic and monitoring, but not screening tests for acute dis-
orders, such as stroke, brain traumatic injury, and infections (of
course, screening tests for predisposition to acute diseases, such
as stroke, would be useful). On the other hand, numerous stud-
ies have demonstrated that, due to high compensatory potential
of the brain, symptoms of chronic neurodegenerative diseases,
such as Alzheimer’s (AD), Parkinson (PD), Huntington (HD)
diseases, vascular and frontotemporal (FTD) dementias occur
10–20 years after the beginning of the pathology. The massive
neuronal death, characteristic of late stages of neurodegenerative
diseases, makes any therapeutic treatment late in the course of
a disease extremely difﬁcult, as illustrated by recent failures of
anti-AD therapies in late stage clinical trials (Sperling et al., 2011;
Pillai and Cummings, 2013). This phenomenon stresses the
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importance of the development of screening tests capable of
detecting such diseases in early asymptomatic stage.
Further, it is instructive to group neurologic diseases accord-
ing to the nature of the underlying physiological and pathological
processes. For example, although molecular mechanisms of vari-
ous neurodegenerative diseases are different, many processes, e.g.,
neurite retraction, dysfunction, and destruction of synapses, fol-
lowed by neuronal death, are characteristic of neurodegeneration
in general (von Bernhardi and Inestrosa, 2008); massive death of
neurons and glial cells accompany initial stages of stroke and brain
traumatic damage (McIntosh et al., 1998; Zheng et al., 2003); dys-
function of dopaminergic neurons is characteristic of addiction to
many drugs (Kreek et al., 2012), etc.
Finally, physical location of pathological processes occurring
during different stages of disease development is important for
the focused search for speciﬁc biomarkers. The neurodegenerative
diseases provide a good example of the diversity of physical loca-
tions involved: although many underlying processes are common
for AD, PD, and FTD, initial pathological events characteristic for
different diseases are localized in different brain areas: hippocam-
pus for AD, midbrain for PD, and frontal lobe for FTD. At later
stages, each disease spreads to new areas of the brain, which signif-
icantly worsens clinical symptoms and narrows treatment options;
this expansion can in principle be used for disease monitoring.
A large number of studies focus on the development of mini-
mally invasive molecular tests for early detection of AD, PD, and
other brain pathologies. These include reports of some encour-
aging early data on the development of blood-based assays for
AD diagnosis based on analysis of a large number of proteins or
antibodies in human blood (Ray et al., 2007; Nagele et al., 2011;
Reddy et al., 2011). In this review we describe new approaches to
developing screening, diagnostic and monitoring tests for neu-
rodegenerative diseases, and other brain pathologies based on
analysis of cell-free microRNA in bodily ﬂuids.
ROLES AND PROPERTIES OF miRNA
miRNA is a class of non-coding RNA, whose ﬁnal product is
an approximately 22 nucleotide-long functional RNA molecule.
miRNA repress translation and regulate degradation of their target
mRNA by binding to complementary regions of messenger tran-
scripts (Grifﬁths-Jones et al., 2006; Bartel, 2009). There are several
programs for in silico analysis of complementarity betweenmiRNA
and mRNA; the lists of possible targets for a miRNA frequently
include hundreds of genes. Hence, based on sequence analysis
alone, a given miRNA can potentially be involved in numerous
different pathologies (for example, see miR-Ontology Database:
http://ferrolab.dmi.unict.it/miro/). All these predictions must be
validated in vivo; in most cases this has not been accomplished yet,
even though experimental data on miRNA roles in epigenetic reg-
ulation of numerous cellular processes are rapidly accumulating
(Siegel et al., 2011; McNeill and Van Vactor, 2012). The following
miRNA properties make them attractive for using in development
of various diagnostic tests.
miRNA are small molecules with higher, e.g., compared to pro-
teins, chances to cross blood–brain, placental, and other barriers
and to appear in bodily ﬂuids. Cell-freemiRNAhave been detected
in plasma, serum, urine, saliva, and milk, where they are protected
by membranes in exosomes and other microparticles, by vari-
ous proteins, lipids and, possibly, other molecules (reviews: Sun
et al., 2012; Zandberga et al., 2013). Although the organ, tissue,
or cell origin of circulating miRNA is difﬁcult to determine in
vivo, it has been shown that many of those circulating miRNA
do not originate in blood cells or cells present in or contacting
with respective bodily ﬂuids (Weber et al., 2010; Duttagupta et al.,
2011). Numerous data on circulating miRNA have recently been
assembled (Russo et al., 2012) and made available via miRandola
database: http://atlas.dmi.unict.it/mirandola/index.html.
More than 1,500 human miRNA have been discovered to date,
and although there are no miRNA exclusively present in a single
tissue or organ, many of them are highly enriched in particu-
lar organs, tissues, and cell types (Barad et al., 2004; Liu et al.,
2004; Baskerville and Bartel, 2005; Beuvink et al., 2007; Land-
graf et al., 2007; Liang et al., 2007; Wang et al., 2007; Castellano
and Stebbing, 2013). Many of miRNA are enriched in the brain
and, importantly for the development of diagnostic tests, vari-
ous miRNA are enriched in different brain areas as well as in
different cell types (neurons and glial cells; Sempere et al., 2004;
Smirnova et al., 2005; Deo et al., 2006; Bak et al., 2008; Trivedi and
Ramakrishna, 2009; Weng et al., 2011; He et al., 2012). Moreover,
certain miRNA are present or even enriched in particular intra-
cellular compartments, such as synapses, dendrites, and axons
(Schratt et al., 2006; Lugli et al., 2008; Schratt, 2009; Edbauer et al.,
2010; Natera-Naranjo et al., 2010; Strickland et al., 2011; Wu et al.,
2011; Pichardo-Casas et al., 2012). A number of the listed above
detailed studies of miRNAexpression in various organs, tissue, and
cell types have been performed prior to identiﬁcation of many
miRNA, and thus there is an obvious need for additional stud-
ies of expression proﬁles of these newly discovered miRNA. In
particular, in situ hybridization studies would be very useful for
mapping miRNA expression in different brain areas, cell types and
intracellular compartments.
Intracellular concentration of miRNA changes in various phys-
iological and pathological processes due to modiﬁcations in their
transcription, maturation, and stability (Iorio and Croce, 2012).
Such changes of miRNA levels in different brain areas are char-
acteristic of many neurodegenerative diseases and other brain
pathologies (reviews: Saugstad, 2010; Fiore et al., 2011).
A number of recent papers review the available data on changes
in miRNA expression in different brain areas involved in AD
development (Fiore et al., 2011). A comprehensive review by
Tan et al. (2013) presents an analysis of the published evidence for
the involvement of miRNA in the four processes playing critical
roles in AD pathogenesis: accumulation of amyloid-β, tau toxic-
ity, inﬂammation, and neuronal death. While some of the results
appear compelling,manymore studies arenecessary to further elu-
cidate the precise roles of individual miRNA in AD pathogenesis
and their involvement in different stages of the disease. Someof the
published data appear contradictory, possibly due to differences in
methods employed for miRNA measurement and normalization
in different studies. For example, both activation and inhibition
of the brain-enriched miR-9 expression in hippocampus of AD
patients have been reported (review: Jin et al., 2013).
Investigations of the miRNA involvement in PD have focused
on analysis of miRNA expression in the midbrain and of miRNA
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role in functioning of dopaminergic neurons and the α-synuclein
synthesis. Downregulation of miR-133b in midbrain of PD
patients (Kim et al., 2007) as well as in mouse models of PD
has been reported in several studies (reviews: Harraz et al., 2011;
Filatova et al., 2012; Mouradian, 2012). miR-7 and miR-153 have
been found to downregulate synthesis of α-synuclein (Junn et al.,
2009; Doxakis, 2010); suppression of the expression of these
miRNA in midbrain of PD patients is expected but has not been
demonstrated yet.
Deregulation of 15 miRNA in the brain of the mouse model of
prion-induced neurodegeneration has been demonstrated (Saba
et al., 2008). Further, changes in miRNA expression caused by or at
least accompanying schizophrenia, autism, cognitive dysfunction,
drug addiction, neuroblastoma, and other neurologic disorders
have been reported (review: Jin et al., 2013).
For the use of miRNA in diagnostics, it is also important that
miRNA secretion varies depending on cellular physiology (Wang
et al., 2009; Pigati et al., 2010; Palma et al., 2012). In addition to
miRNA release into extracellular space and subsequent appearance
in the bodily ﬂuids due to cell death, miRNA appear in circula-
tion due to blebbing of apoptotic bodies, budding and shedding
of microvesicles, active secretion in the form of exosomes and
of miRNA complexes with proteins (AGO2, NPM1, and others)
and high density lipoproteins (HDL; reviews: Sun et al., 2012;
Zandberga et al., 2013). All these forms of cell-free miRNA
are highly stable in the bloodstream and other bodily ﬂuids.
The secretion of miRNA is selective and can be signiﬁcantly
changed by various pathological processes. For example, changes
in the spectrum of miRNA secreted in exosomes from prion-
infected neuronal cells, as compared to uninfected cells, have been
demonstrated (Bellingham et al., 2012).
IDENTIFICATION OF POTENTIAL miRNA BIOMARKERS IN
BODILY FLUIDS
The development of screening and diagnostic tests for various
diseases based on analysis of miRNA in bodily ﬂuids – mainly in
plasma or serum, but also in urine, saliva, CSF, and milk – is a very
active area of research. Below are three approaches commonly used
in such studies, including studies in the area of neurodegenerative
diseases:
(1) Measurement of hundreds miRNA in a bodily ﬂuid from
patients with a pathology of interest and from control subjects
using miRNA array or next generation sequencing (NGS; Qin
et al., 2013). An obvious advantage of this approach is that huge
numbers of various miRNA can be analyzed. Detection of miRNA
sequence variations, which can be informative, e.g., for tumor
diagnostics, is another advantage of NGS (Williams et al., 2013).
Many potential biomarkers have been found by these techniques.
However, the miRNA array-based and sequencing techniques are
not sufﬁciently sensitive to detect many miRNA whose concen-
tration in bodily ﬂuids is relatively low. Usually only 30–40%
of plasma or serum miRNA detectable by an individual RT-
PCR is measurable by various miRNA arrays. This is also true
for the RT-PCR-based array, largely due to signiﬁcantly lower
amounts of plasma analyzed by array compared to individual RT-
PCR. In addition, reproducibility is very important for screening
tests addressing early disease stages when changes in biomarker
concentrations usually are not high. Unfortunately, variability of
miRNA array tests is signiﬁcantly higher than that of the indi-
vidual miRNA RT-PCR (Leidner et al., 2013). As a consequence,
potential biomarkers selected by array analysis have to be con-
ﬁrmed by RT-PCR, and indeed in many cases the array data is not
conﬁrmed. Further, even when miRNA array-selected potential
biomarkers are validated by RT-PCR, they cannot be automati-
cally considered useful for screening or diagnostic purposes. Most
of the miRNA detectable in bodily ﬂuids by arrays are ubiq-
uitous miRNA expressed in all or many tissues, and many of
them derive from blood cells (Pritchard et al., 2012; Leidner et al.,
2013); the detection of changes in their concentrations in patients
with one pathology does not mean that the same miRNA cannot
be involved in other diseases of different organs. Many miRNA
are associated with a particular pathology type, such as cancer,
inﬂammation, hypoxia, etc., and changes in their concentration in
bodily ﬂuids can be associated with diseases of different organs.
For example, changes of miR-155 concentrations were found in
the bloodstream of patients with breast, esophageal, lung, pan-
creatic cancers and lymphomas (Blair and Yan, 2012; Xie et al.,
2013). Level of miR-21 increases in plasma/serum of patients with
osteosarcoma, bladder, esophageal, gastric, lung, breast, colorec-
tal cancers, neck squamous cell carcinoma, and other tumors
(Farazi et al., 2011; Blair and Yan, 2012; Xie et al., 2013). It fol-
lows that the potential biomarkers found by miRNA arrays should
be also tested in other pathologies, not only in healthy control
subjects.
(2) The second approach is based on analysis of disease-speciﬁc
miRNA identiﬁed by comparison of miRNA isolated from patho-
logic and normal tissue, organ, or cell type. Here, subsequent to
identiﬁcation of disease-speciﬁc miRNA, e.g., by array followed
by RT-PCR, their presence in bodily ﬂuids is analyzed. There
are obvious advantages to this strategy. First, a limited number
of circulating miRNA should be tested, which makes the use of
individual RT-PCR appropriate, thus increasing sensitivity and
reproducibility of the analysis. Second, an observation of a cor-
relation between changes in miRNA concentrations in a bodily
ﬂuid and in an organ involved in pathology directly suggests that
the miRNA is a suitable biomarker for screening tests. However,
such a correlation does not always exist and sometimes miRNA
concentrations in a bodily ﬂuid and in a target organ change in
opposite directions (Boeri et al., 2011; Cuk et al., 2013). This phe-
nomenon can be explained by several factors: (i) if pathology is
caused by, or associated with, the change in concentration of a
ubiquitous miRNA, the effect of the pathology on the concen-
tration of this miRNA in circulation could be very limited, since
only a small fraction of the miRNA in circulation comes from
the affected organ or tissue; (ii) changes in miRNA concentra-
tion due to pathology development can be accompanied by much
more prominent opposite changes in miRNA secretion/excretion,
which neutralizes or even overcomes the effect of changed miRNA
expression. Of course, these limitations do not preclude success-
ful use of the described approach for the discovery of circulating
miRNA biomarkers. In the area of neurodegenerative and other
neurologic pathologies this approach can be especially productive
for the miRNA biomarker discovery in CSF (see below) because:
(i) CSF is not separated from brain by the blood–brain barrier;
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and (ii) the amount of miRNA secreted or excreted from other
organs to CSF is very limited (Cogswell et al., 2008).
(3) The third approach was proposed recently for searching
for biomarkers of mild cognitive impairment (MCI), AD, and
other neurodegenerative diseases (Sheinerman et al., 2012; Shein-
erman and Umansky, 2013). It is based on analysis of circulating
brain-enriched miRNA in bodily ﬂuids, e.g., in plasma. Restrict-
ing the analysis to brain-enriched miRNA signiﬁcantly increases
the chances that any observed changes in concentrations of these
miRNA in plasma are caused by brain-related processes. In addi-
tion, it is proposed to include miRNA enriched or at least present
in neurites and synapses, i.e., neuronal compartments, which are
involved in neurodegenerative diseases from early stages of pathol-
ogy development, years before massive death of neurons. It could
be also useful to search for miRNA enriched in the brain area,
which suffers ﬁrst during development of a particular disease,
e.g., in hippocampus for AD and in midbrain for PD potential
biomarkers. As a number of miRNA to be investigated is lim-
ited, RT-PCR can be used here, which is critically important since
plasma concentration of many brain-enriched neurite/synapse
miRNA is too low to be reliably detectable by miRNA arrays. The
advantages and disadvantages of the three approaches described
above are summarized in Table 1.
NORMALIZATION OF miRNA CONCENTRATION IN BODILY
FLUIDS
The concentration of miRNA detected in bodily ﬂuids depends
on many biological and technical factors. Biological factors
include miRNA levels in various tissues, intensity of secre-
tion and excretion into extracellular space, forms of circulating
miRNA (exosomes and other vesicles, complexes with proteins
and lipids) affecting their ability to cross various barriers, e.g.,
blood–brain, placental, and kidney barriers, and miRNA stabil-
ity and half-life in the bloodstream. Technical factors include
variability during bodily ﬂuid collection and storage, methods
used for miRNA extraction, and the presence in bodily ﬂuids of
various factors affecting miRNA puriﬁcation and RT-PCR. As a
consequence, the importance of miRNA normalization is cur-
rently broadly recognized (Meyer et al., 2010). At the same time
no single normalization method is commonly accepted. Several
methods of circulatingmiRNAnormalization have been described
in literature:
(1) Normalization per spiked miRNA, which is absent in the
investigated species, e.g., C. elegans or plant miRNA absent in
mammalian cells (Sarkar et al., 2009; Kroh et al., 2010; Sanders
et al., 2012). SuchmiRNA is spiked into abodily ﬂuid after addition
of a lysing solution that inhibits nuclease activity and then is used
as a normalizer by theCt approach compensating for variability
caused by RNA extraction and the possible presence of RT-PCR
inhibitors.
(2) Normalization per ubiquitous and least variable circulating
miRNA (Peltier and Latham, 2008; Latham, 2010; Lardizábal et al.,
2012). Thismethod is used for comparing circulatingmiRNA con-
centrations in controls and in one or a relatively small number of
pathologies, which are not associated with changes of a normalizer
miRNA. For example, miR-16 is widely used as such normalizer
(Kroh et al., 2010). One needs to be mindful, however, that miR-16
is involved in regulation of apoptosis and its expression is changed
in many pathologic processes, which leads to changes of its con-
centration in plasma and other bodily ﬂuids (Schaefer et al., 2010;
Katsuura et al., 2012; Wang et al., 2012b). Similar considerations
apply to other miRNA normalizers of this type.
(3) Normalization per other (not miRNA) small RNA, mainly
small nuclear or small nucleolar RNA. This approach was often
used in earlier studies of circulating miRNA, and is still used
although more rarely (Sanders et al., 2012). In addition to prob-
lems similar to the ones described in the previous paragraph
(changes in the RNA concentration associated with some patholo-
gies),the utility of this approach is limited by the fact that these
RNA are larger than miRNA, bound to different proteins, and
their stability is different from that of miRNA (Lardizábal et al.,
2012).
Table 1 | Current approaches to analysis of miRNA in plasma.The same approaches can be used for miRNA analysis in different body ﬂuids (urine,
saliva, and milk).
miRNA array/NGS Disease-specific analysis Organ/cell-specific analysis
Steps
1. miRNA isolated from plasma
2. Array analysis
3. RT-PCR veriﬁcation
4. Validation
1. miRNA isolated from pathologic and normal tissue
2. Array analysis
3. RT-PCR veriﬁcation
4. Selected miRNA analyzed in plasma
5. Validation
1. miRNA isolated from plasma
2. RT-PCR analysis of organ, cell-enriched miRNA
3. Validation
Advantages
• 100s of miRNA tested • Disease-related miRNA tested
• High sensitivity
• Organ/cell-speciﬁc miRNA tested
• High sensitivity
Disadvantages
• Low sensitivity
• High variability
• Same miRNA can be involved in pathologies of various organs
• miRNA levels in tissue and plasma do not always correlate
• Selected miRNA can be undetectable in plasma
• miRNA biomarkers not enriched in target
organs or cells can be missed
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(4) If a large number of miRNA is analyzed, usually by
miRNA arrays, normalization per average of all miRNA can be
used (Mestdagh et al., 2009; D’haene et al., 2012; Blondal et al.,
2013).
(5) Finally, in recent years application of “miRNA pair”
approach is becoming increasingly popular (Boeri et al., 2011;
Hennessey et al., 2012; Matthaei et al., 2012; Sheinerman et al.,
2012). In this case, ratios (Ct) of each miRNA to each other
miRNA measured in a given experiment is calculated, and pairs,
which provide the highest accuracy in differentiating patients
with a disease of interest from controls, are selected. A vari-
ant of the approach is based on the use of miRNA enriched in
the organ of interest (Sheinerman et al., 2012; Sheinerman and
Umansky, 2013). The rationale for the approach is as follows.
First, any pathology is usually associated with upregulation of
some miRNA and downregulation of other miRNA, thus consid-
ering miRNA pairs may increase test sensitivity and speciﬁcity.
Second, use of the pair of, rather than one, miRNA enriched
in the same organ decreases potential overlap with pathologies
of other organs. Third, one can expect that changes unrelated
to or non-speciﬁc for a pathology of interest, such as changes in
blood supply, blood–brain permeability (for neurological patholo-
gies) and others, will be better compensated for by using the pair
of miRNA enriched in the same organ. This approach is par-
ticularly promising for neurodegenerative and other neurologic
diseases. For example, combination of neurite/synapse miRNA
with a neuronal body miRNA may be informative for evalu-
ating disease progression from synapse destruction to neuronal
death. The changes in relative concentrations of miRNA enriched
in different brain areas or different cell types (e.g., neurons
and glial cells) may be an indicator of disease progression, and
so on.
In summary, data normalization is an extremely important step
in developing tests based on analysis of circulating miRNA, and as
such it represents an active area of research.
SEARCH FOR miRNA BIOMARKERS FOR NEUROLOGIC
DISEASES
There are numerous recent reviews on miRNA role in brain
development, normal brain aging, and various neurological dis-
orders (Krichevsky et al., 2003; Gascon and Gao, 2012; Mellios
and Sur, 2012; Salta and De Strooper, 2012; Smith-Vikos and
Slack, 2012; Wang et al., 2012a; Xu et al., 2012; Dimmeler and
Nicotera, 2013; Moreau et al., 2013). Here we concentrate on
circulating cell-free miRNA as potential biomarkers for diagnos-
ing neurologic diseases. Despite well-recognized need in early
detection of neurodegenerative diseases and other neurological
disorders and great promise of circulating miRNA as poten-
tial biomarkers, there are relatively few publications in the
area. There could be several explanations for this phenomenon,
including an observation that concentration of many circu-
lating cell-free brain-enriched miRNA in plasma, serum, and
other bodily ﬂuids is relatively low and thus they are not eas-
ily detectable by commonly used miRNA arrays. As mechanisms
of miRNA appearance in CSF and bloodstream are different,
below we separately describe the existing data for these two bodily
ﬂuids.
CELL-FREE miRNA IN CSF AND CNS DISORDERS
The presence of miRNA inCSFwas ﬁrst demonstrated byCogswell
et al. (2008). Cogswell et al. (2008) also reported changes in levels
of manymiRNA inCSFofADpatientswhen compared to controls.
The authors came to a conclusion, however, that the major source
of miRNA detected in CSF are immune cells present in CSF since
“there was no obvious relationship between the miRNAs altered in
CSF and the absolute levels in sites of AD mediated destruction or
the directional changes in those regions.”Many miRNA, including
those that are highly enriched in brain, were not detectable in CSF
by methods used. In another study devoted to the same matter
the increase in levels of pro-inﬂammatory miR-146a and miR-
155 in CSF of AD patients compared to age-matched controls
as well as upregulation of neuron-enriched miR-9 and miR-125b
was reported (Alexandrov et al., 2012). Interestingly, Lukiw et al.
(2012) also demonstrated upregulation of miR-145b and miR-155
in human neuronal–glial primary cocultures 12 and 36 h after
stress treatment and proposed that extracellular miRNA can be
involved in spreading of AD inﬂammatory signaling.
Several studies describe changes in concentration of CSF
miRNA in patients with different brain tumors. miR-15b andmiR-
21 were differentially expressed in CSF from patients with gliomas,
compared to controls with various neurologic pathologies, includ-
ing patients with primary CNS lymphoma and carcinomatous
brain metastasis (Baraniskin et al., 2012). The changes in expres-
sion and plasma/serum levels of both miR-15b and miR-21 are
commonly associated with different types of cancers and are not
speciﬁc for gliomas. However, it seems unlikely that their con-
centrations in CSF can be strongly affected by non-CNS tumors.
This conjecture needs to be proven for these miRNA to be used
as glioma biomarkers. Teplyuk et al. (2012) found a signiﬁcant
increase of miR-10b and miR-21 levels in CSF of patients with
glioblastoma and brain metastasis of breast and lung cancers,
compared with various non-neoplastic conditions, such as mem-
ory problem, dementia, PD, encephalitis, and others. These two
miRNA were also signiﬁcantly upregulated in glioblastoma, com-
pared to normal brain. The use of CSF levels of seven miRNA –
miR-10b, miR-21, miR-125b, miR-141, miR-200a, miR-200b, and
miR-200c – permitted the authors to achieve high accuracy in sep-
aration between all classes of samples. Again, only miR-125b from
this list is a brain-enrichedmiRNA; all othermiRNA are associated
with carcinogenesis itself, so their usefulness as potential biomark-
ers is based on their presence in CSF,which is isolated from tumors
located in other organs outside of CNS.
Microparticles containing miRNA, including brain-enriched
ones, have been found in CSF and the spectrum of miRNA
detectable in CSF is changed after brain injury (Patz et al., 2013).
miR-451wasdetected inCSFmicroparticles only after brain injury,
which can be explained by more effective secretion of this miRNA
from abnormal cells (Pigati et al., 2010).
CELL-FREE miRNA IN PLASMA AND SERUM AND CNS DISORDERS
Due to massive damage and death of neurons and glial cells the
concentration of circulating brain-enriched miRNA is dramati-
cally increased in the bloodstream after a stroke. For example, in
the rat model, the plasma level of miR-124 is up to 150 times
higher than in plasma of sham-operated animals (Laterza et al.,
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2009). Of course, one cannot expect such large changes of miRNA
biomarker levels in plasma/serum from patients with chronic,
slowly developing neurodegenerative diseases, such as AD. Per-
haps, this consideration explains why, in spite of the huge need
in a minimally invasive test for early detection of AD, there are
only two publications devoted to the use of circulating miRNA for
diagnosis of this pathology.
Geekiyanage et al. (2012) compared concentrations of ﬁve
miRNA, namely miR-137, miR-181c, miR-9, miR-29a, and miR-
29b in serum of MCI and AD patients with their levels in serum
of age-matched controls. The choice of miRNA was based on the
previous study (Geekiyanage and Chan, 2011) that demonstrated
their involvement inADpathogenesis anddownregulationof these
miRNA in the brain cortex of sporadicADpatients. UsingRT-PCR
and normalization per spiked cel-miR-39 and internal miR-22,
miR-191, and miR-126 the authors demonstrated that the levels
of miR-137, miR-181c, miR-9, miR-29a, and miR-29b are sig-
niﬁcantly lower in serum of MCI and AD patients, compared to
controls. Since each group of patients and controls included only
seven subjects, sensitivity and speciﬁcity of MCI andAD detection
could not be calculated.
Sheinerman et al. (2012) investigated the use of circulating
miRNA for early detection of MCI. Since neuronal death, a late
event in the development of AD and other neurodegenerative
diseases, is preceded by metabolic changes, neurite retraction,
synaptic dysfunction, and synapse loss, the authors suggested
that these processes could cause excessive secretion and excre-
tion of miRNA from brain areas involved in the pathology. Thus,
brain-enriched miRNA, including neurite- and synapse-enriched
miRNA were measured in plasma of MCI and AD patients and
age-matched control subjects. Described above “miRNA pair”
approach was used for data normalization. In the preliminary
experiments 32 miRNA were analyzed, then 13 most promis-
ing miRNA were selected for the feasibility study. Finally, two
sets of biomarker miRNA pairs were identiﬁed: the “miR-132
family” (miR-128/miR-491-5p, miR-132/miR-491-5p, and mir-
874/miR-491-5p) and the “miR-134 family” (miR-134/miR-370,
miR-323-3p/miR-370, and miR-382/miR-370). Each biomarker
pair included as numerator neurite/synapse-enriched miRNA.
These potential biomarkers differentiated MCI from age-matched
controls with sensitivity and speciﬁcity of 79–100% (miR-132
family) and 79–95% (miR-134 family). In a small longitudinal
study (19 subjects), the identiﬁed miRNA biomarker pairs suc-
cessfully detected MCI in majority of patients at asymptomatic
stage 1–5 years prior to clinical diagnosis. MCI is a heterogeneous
syndrome. On average, 10–15% of MCI patients annually con-
vert to dementia. About 80% of dementias are caused by AD and
the rest of dementia patients are diagnosed with other neurode-
generative diseases. It is perhaps not surprising then that both
sets of miRNA pairs also differentiated AD from age-matched
control. The biomarkers do not distinguish AD from MCI, how-
ever, indicating that these biomarkermiRNApairs detect processes
characteristic of various neurodegenerative pathologies (synapse
destruction?) but not AD-speciﬁc events. Interestingly, these
biomarker pairs also appear useful for detecting age-related brain
changes. The reported results await conﬁrmation in larger clinical
studies.
One study (Gaughwin et al., 2011) described a search for a
plasma miRNA, which could be used for early diagnosis of HD.
The authors tested many miRNA regulated by mutant HTT pro-
tein and found that one of these miRNA, miR-34b, is signiﬁcantly
elevated in plasma from carriers of mutant HTT prior to symp-
tom onset. However, it is unclear if miR-34b can be a speciﬁc
biomarker for HD, since this miRNA is expressed in many tissues,
being especially enriched in pulmonary system, Fallopian tubes,
and testicles, and is also deregulated in various pathologies.
Several groups (Haghikia et al., 2012; Siegel et al., 2012; Gandhi
et al., 2013; Ridolﬁ et al., 2013) reported promising results regard-
ing potential use of circulating miRNA in CSF or bloodstream
for diagnosis of multiple sclerosis (MS). Since MS is an autoim-
mune neurodegenerative disease, one can expect that concentra-
tion of both brain-enriched miRNA and of inﬂammation and
immune system-associated miRNA could be changed in CSF and
plasma/serum. Currently, the majority of the discovered potential
biomarkers belong to the latter group: inﬂammation and immune
system associated miRNA.
A limited number of studies report analyses of circulating
miRNA in plasma or serum of patients with various neurolog-
ical and psychological disorders, such as depression (Li et al.,
2013), bipolar disorder (Rong et al., 2011), and schizophrenia (Shi
et al., 2012), suggesting that the study of circulating miRNA in
plasma/serum for diagnosis of neurological disorders represents a
promising direction for further more detailed investigations.
SUMMARY AND PERSPECTIVES
In spite of the rapidly growing number of publications on diag-
nostic applications of circulating cell-free miRNA, their use for
screening of CNS diseases is in early stages of development.
One factor impeding the progress in the ﬁeld is the difﬁculty
of comparing the data reported by different groups due to the
use of different methods for searching for potential circulating
miRNA biomarkers, different techniques for miRNA measure-
ment and data normalization. Broad acceptance of best practices
and uniform methods for analysis of circulating miRNA and the
development of statistical apparatus for comparing the results
obtained by different techniques will be important to overcome
the problem.
Further, whenmiRNAarrays are used for initialmiRNA screen-
ing, many tissue-enriched miRNA are not detectable and, as a
consequence, ubiquitous miRNA, including miRNA associated
with common pathologic processes such as carcinogenesis or
inﬂammation, are often selected as potential biomarkers. These
miRNA can successfully differentiate patients with a particular
disease from healthy control subjects, but not necessarily from
patients with similar pathologies of other organs, since it is highly
likely that the plasma or serum levels of these miRNA will also
be affected in such patients. From this perspective, searching for
miRNA biomarkers in CSF has advantages for detecting CNS dis-
orders, similar to advantages of using stool miRNA for detecting
colon diseases (Ahmed et al., 2013): in each of these cases miRNA
come from the organ of interest. The invasiveness of CSF collec-
tion, however, precludes using it for primary screening, and thus
emphasis needs to be placed on the development of screening tests
based on analysis of plasma or serum.
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An analysis of data in literature suggests a number of opti-
mization steps to increase the chances of success for such efforts.
First, the use of brain-enriched miRNA for CNS disorders should
increase biomarker speciﬁcity. This thesis is supported by data
obtained for other organs. For example, increase in plasma/serum
concentration of liver-enriched miR-122 is very common in
patients with pathologies of this organ (Zhang et al., 2010), and
increase in plasma/serum concentration of heart-enriched miR-
1, miR-133a, miR-133b, or miR-499-5p is characteristic of acute
myocardial infarction and some other cardiac pathologies (Tijsen
et al., 2012). Second, combination of several circulating miRNA
biomarkers can increase test speciﬁcity, since even expression of
ubiquitous miRNA varies from organ to organ and one can expect
that spectrums of concentration of several miRNA biomark-
ers will be different for various pathologies of different organs.
For example, Li et al. (2011) made an interesting observation of
the age-dependent increase of miR-34a concentration in brain,
peripheral blood mononuclear cells, and plasma. This miRNA,
however, cannot be used as a sole biomarker of aging, since
its concentration in plasma is changed in patients with tumors
of various locations and with other pathologies. At the same
time, in combination with mir-132 and miR-134 biomarker fam-
ilies described above, this miRNA could be a helpful additional
biomarker. Finally, it can be useful to combine tissue-enriched
miRNA with miRNA associated with a common pathology type,
e.g., carcinogenesis.
The data reviewed herein suggests strongly that the analysis of
cell-free miRNA in bodily ﬂuids is a highly promising approach
for developing minimally invasive screening tests for CNS disor-
ders. A different question is whether circulating miRNA represent
a promising class of molecules for the prognosis of neurological
disease outcomes and for disease and treatment monitoring. Nat-
urally, diagnostic biomarkers can be used for disease monitoring if
same pathologic processes underlie the development of the disease
during different disease stages. The use of diagnostic biomarkers
for disease monitoring is more problematic, however, if disease
progression is caused by involvement of new pathologic processes.
AD is a good example of such a disease: (i) the pathology is initi-
ated by not fully understoodmetabolic abnormalities, (ii) these are
followed by morphological changes in particular brain areas, such
as formation of amyloid plaques and tau protein tangles, neurite
retraction, dysfunction, and destruction of synapses, (iii) ﬁnally
neurons are dying, and pathology expands to new brain areas and
cell types. Thus, it is unlikely that different stages of AD can be
differentiated by the same biomarkers. The situation is also com-
plicated by the fact that some processes, e.g., synapse destruction,
are common for different pathologies, including normal brain
aging and other neurodegenerative diseases. The detection of such
commonprocesses is clearly useful formonitoring of normal brain
aging and diagnosis of MCI, which is a syndrome characteristic of
early stage of various neurodegenerative diseases. However, such
a test will not predict MCI outcome. This goal could be accom-
plished by other tests, such as CSF protein analysis and/or imaging
techniques, or by different miRNA biomarkers speciﬁc for various
AD stages. For example, AD expansion to new brain areas and cell
types can be monitored by circulating miRNA enriched in those
brain areas and cell types. The switch from synapse destruction to
neuronal death can potentially be detected by changes of ratios in
plasma of cell-free synapse-enriched and neuronal body miRNA,
and so on. Of course, all such proposals need be tested, preferably
in longitudinal studies.
We hope the advances in the analyses of circulating miRNA
reviewed here will lead to more efforts toward using miRNA as
biomarkers of neurodegeneration, of other neurologic patholo-
gies, and of normal brain aging, andwill facilitate the development
of screening, predictive, and monitoring tests for these diseases.
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